Menu Search
Equities

Boston Scientific Corp

BSX:NYQ

Boston Scientific Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)90.00
  • Today's Change-1.50 / -1.64%
  • Shares traded5.43m
  • 1 Year change+62.37%
  • Beta0.8055
Data delayed at least 15 minutes, as of Nov 22 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Boston Scientific Corp grew revenues 12.29% from 12.68bn to 14.24bn while net income improved 128.22% from 698.00m to 1.59bn.
Gross margin69.09%
Net profit margin11.24%
Operating margin17.01%
Return on assets4.96%
Return on equity9.06%
Return on investment5.85%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Boston Scientific Corp fell by 71.00m. However, the company earned 2.50bn from its operations for a Cash Flow Margin of 17.58%. In addition the company generated 5.00m cash from financing while 2.57bn was spent on investing.
Cash flow per share2.04
Price/Cash flow per share44.61
Book value per share14.05
Tangible book value per share-0.0536
More ▼

Balance sheet in USDView more

Boston Scientific Corp has a Debt to Total Capital ratio of 34.19%, a lower figure than the previous year's 44.40%.
Current ratio1.48
Quick ratio1.02
Total debt/total equity0.5256
Total debt/total capital0.3419
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 140.57%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)-1.29
EPS (TTM) vs
TTM 1 year ago		48.30
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.